Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
Functional Screen of the Fanconi Anemia Pathway in Cancer Cells by Fancd2 Immunoblot
Michiel S. Van der Heijden, Jonathan R. Brody, and Scott E. Kern
volume 3 | issue 6
june 2004Pages: 534-537
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
The Fanconi genes BRCA2, FANCC and FANCG are mutated in a subset of pancreatic cancer. Additionally, the Fanconi pathway is inactivated, probably by methylation of the CpG island of FANCF, in a subset of ovarian cancers. The competence of the proximal Fanconi pathway was screened by an assay of Fancd2 monoubiquitination in a panel of 35 cancer cell lines: 15 breast, 6 prostate, 8 head and neck, 4 biliary cancers, an astrocytoma and a large cell lung carcinoma. Two (6 %) cell lines displayed abnormal Fancd2 monoubiquitination: the head and neck cancer cell line FaDu and the breast cancer cell line UACC812. In UACC812, we found that FANCF was not expressed. In the case of FaDu, no explanation for the abnormal Fancd2 monoubiquitination was found. FaDu had a moderately increased sensitivity to mitomycin C, as compared to two Fanconi proficient head and neck cancer cell lines. These studies extend the number of tumor systems having Fanconi pathway defects. Future studies should aim to investigate the involvement of defects in the Fanconi pathway in breast and head and neck cancer.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.